Schrodinger, Inc. (SDGR) - Q1 2025 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended March 31, 2025. Schrodinger, Inc. operates two primary segments: Software (licensing physics-based computational platforms for drug and materials discovery) and Drug Discovery (advancing proprietary programs and collaborations). The company is a large accelerated filer with no preferred stock outstanding.
Key Financial Metrics
| Metric | Q1 2025 | Q1 2024 |
|---|---|---|
| Total Revenue | $59.6 million | $36.6 million |
| Net Loss | $(59.8) million | $(54.7) million |
| Diluted Net Loss Per Share | $(0.82) | $(0.76) |
| Gross Profit | $31.1 million | $18.9 million |
| Operating Cash Flow | $144.1 million (Provided) | $(39.3) million (Used) |
| Cash & Marketable Securities | $512.1 million | $362.1 million (Est.) |
| Accumulated Deficit | $(585.3) million | $(525.5) million |
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 63% year-over-year, driven by a 46% increase in Software revenue ($48.8M) and a 237% surge in Drug Discovery revenue ($10.7M).
- Novartis Collaboration: The significant increase in Drug Discovery revenue is primarily attributed to the new collaboration with Novartis Pharma AG, which began in November 2024. The company recognized $5.7 million in revenue from this agreement in Q1 2025.
- Software Mix: On-premise software revenue grew 44% and hosted software revenue grew 52%, while professional services revenue declined 31% due to project timing.
- Equity Investment Volatility: The company recorded a non-cash loss of $13.1 million due to a decline in the fair value of its investment in Structure Therapeutics. This contrasts with an $8.1 million gain in the prior year period.
- Cash Flow Reversal: Operating cash flow swung from a $39.3 million outflow in Q1 2024 to a $144.1 million inflow in Q1 2025. This was largely driven by a $215.3 million decrease in accounts receivable (collections) and the timing of the Novartis upfront payment recognition.
Guidance, Outlook, and Risks
- Liquidity: Management believes existing cash, cash equivalents, and marketable securities ($512.1 million) are sufficient to fund operations for at least the next 24 months.
- Clinical Pipeline:
- SGR-1505 (MALT1 inhibitor): Phase 1 trial in B-cell malignancies is ongoing; initial data expected in Q2 2025.
- SGR-2921 (CDC7 inhibitor): Phase 1 trial in AML initiated; initial data expected in H2 2025. Received Fast Track and Orphan Drug designations.
- SGR-3515 (Wee1/Myt1 inhibitor): Phase 1 trial in solid tumors initiated; initial data expected in H2 2025.
- Key Risks:
- Profitability: The company has a history of significant operating losses and expects to incur losses for several years.
- Regulatory & Political: Risks include potential FDA workforce reductions and budget cuts announced by the new U.S. administration, which could delay reviews. Additionally, new tariffs and trade restrictions (including those on China) pose supply chain and cost risks.
- Collaboration Dependency: Future revenue is heavily dependent on the success of collaborators (e.g., Novartis, BMS) in achieving milestones and commercializing products.
Investor Verification Checklist
- Verify the sustainability of the Q1 2025 operating cash flow surge, specifically the $215M reduction in accounts receivable, to ensure it reflects collections rather than one-time adjustments.
- Monitor the fair value of the Structure Therapeutics equity investment, which caused a $13.1M non-cash loss, for continued volatility.
- Track the progress of the Novartis collaboration ($150M upfront, $2.27B potential milestones) as a primary revenue driver.
- Assess the impact of the new U.S. administration's FDA budget cuts and workforce reductions on the timeline for SGR-1505, SGR-2921, and SGR-3515 clinical data readouts.
- Review the company's exposure to Chinese CROs and suppliers in light of new tariffs and the potential passage of the BIOSECURE Act.